Investing in Innovative Health Solutions
Know Labs, Inc. (NYSE American: KNW) has made a significant move by announcing a direct offering that aims to enhance its pursuit of revolutionary medical diagnostic technologies. With the registration for a direct placement of $300,000 in gross proceeds, Know Labs is poised to advance its mission in non-invasive medical technology, a field that continues to gain attention for its potential to improve health diagnostics.
Details of the Direct Offering
This recent offering consists of a unit package, including one share of the company's stock and one warrant. Each unit was priced at $0.24 per share, with the included warrant also exercisable at the same price. Such financial structuring provides a mechanism for potential investors to participate in the company’s future growth. The warrants will expire five years from the date of issuance and come with a cashless exercise option under specific circumstances, allowing flexibility and attractiveness for potential shareholders.
Regulatory Compliance and Market Confidence
Know Labs is conducting these transactions under its effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). The direct offering complies with all necessary regulations, providing investors with a legitimate opportunity to engage with the company's ambitious trajectory. It’s important to note that the offering adheres to NYSE American rules regarding pricing, demonstrating a commitment to market standards and transparency.
Company Background and Future Directions
Know Labs, Inc. is at the forefront of innovation, capitalizing on its proprietary technology that leverages spectroscopy to analyze molecular signatures non-invasively. This technology places it in a unique position to enter diverse markets, including its first anticipated product—a non-invasive glucose monitor aimed at providing real-time glucose monitoring to users without the discomfort of traditional blood tests. The technology shows promise in potentially transforming diabetes management, making it a compelling venture for investors looking towards health tech innovations.
Contacts for Further Information
For more inquiries regarding the recent offering or the company’s innovative technologies, Know Labs has established communication channels that provide access to their team. Interested parties can reach their Secretary at Know Labs, Inc., located at 619 Western Avenue, Suite 610, or contact them by phone for more detailed discussions surrounding their offerings and future products.
Frequently Asked Questions
What is Know Labs, Inc.'s recent funding announcement about?
Know Labs, Inc. has announced a $300,000 registered direct offering to bolster its non-invasive medical technology development.
What are the components of the offering?
The offering includes a share of stock and a warrant, both priced at $0.24 each.
How will the proceeds be utilized by the company?
The funds are intended to further develop Know Labs’ innovative diagnostic technologies, particularly in non-invasive health monitoring solutions.
What is unique about Know Labs' technology?
Know Labs utilizes spectroscopy to enable non-invasive monitoring, which offers a significant advantage over traditional testing methods.
Who can investors contact for more information?
Investors can contact Know Labs directly through their office or website for detailed inquiries about their offerings and technologies.
